Pyrexar Helps Spain Lead the Way in Thermal Therapy
Pyrexar Medical announces a distribution agreement with Spain's Magna Medic Systems to bring thermal oncology products to the region.
Salt Lake City, UTAH, September 17, 2015 (Newswire.com) - Pyrexar Medical, leaders in thermal therapy systems for cancer treatment, announced that it has signed an exclusive distribution agreement with Magna Medic Systems of Spain.
Magna Medic Systems is an ESHO (European Society of Hyperthermic Oncology) partner and the driving force behind the creation of the thermal oncology working group of SEOR (Spanish Society of Radiation Oncology). SEOR is a group of 60 oncologists looking to improve cancer treatment outcomes with the latest in cancer fighting technologies.
We are pleased to have the caliber of people at Magna working with us. Their dedication and passion to improve cancer outcome meshes well with our goals at Pyrexar. With their help, we will continue to promote the use of hyperthermia in Spain and throughout the region.
Mark, Falkowski
Hyperthermia, also known as thermal therapy, is clinically proven to boost the effectiveness of radiation therapy and chemotherapy in cancer patients. Thermal therapy works by increasing blood flow and oxygenation to the tumor site. As an adjunct therapy to radiation treatment, hyperthermia increases the number of oxygen radicals that can be produced to destroy cancer cells. When used with chemotherapy, thermal therapy treatments sensitize the tumor site allowing more cancer killing agents to target the tumor.
According to Magna Medic general manager Elie Helou, the company has three main objectives in bringing thermal therapy to the country. 1) To improve the quality of life for those who are affected by cancer; 2) to educate the oncology community of the increased survival benefits when combining hyperthermia with radiation therapy and chemotherapy; 3) provide the best in hyperthermia technology and education to the oncology community and their patients. “After extensive market evaluation, we chose Pyrexar to help us achieve our goals,” says Mr. Helou. “We look forward to making an impact in the marketplace”.
“We are pleased to have the caliber of people at Magna Medic working with us.” said Mark Falkowski, CEO of Pyrexar Medical. “Their dedication and passion to improve cancer outcomes meshes well with our goals at Pyrexar. With their help, we will continue to promote the use of hyperthermia in Spain and throughout the region.”
ABOUT MAGNA MEDIC SYSTEMS
Based in Málaga, Spain, Magna Medic works in the health sector specializing in technology for oncology groups. A member of SEOR hyperthermia group, the company is currently seeking hyperthermia clinical trials and is a promoter of the university masters of hyperthermia program. See them on the web at www.magnamedic.com
ABOUT PYREXAR MEDICAL:
Pyrexar Medical is a pioneer and worldwide market leader in the development and manufacture of innovative and highly effective thermal therapy/hyperthermia treatment systems with established distribution and support networks around the world. PYREXAR HyperThermia (PYREXAR HT) treatments, proven in multiple clinical trials over the last 30 years, increase the effective dose of ionizing radiation in solid tumors up to 3X without increasing toxicity to healthy tissues.
To find out more about Pyrexar Medical products, visit our webpage www.pyrexar.com.